Member Info for jayhayes

Hahaha yes another one buys the dust

We do risk! Communication is so poor

We both know why….. we haven’t made an sales and STIll aaait fda

Thanks midsummer! Haha dam running out of friends

Sound il do that. Ill sell I’m listen to you like people listen to me.. haha funk sake

You can’t have a moan! I’m invested hell of a lot of money and time! Always give good info if i find it…. Moan and I’m a baddy with no holding….. fml I’m gonna go bed crying

Seen on the news who should of warned us earlier

I don’t hold

Hahaha

Never recovered did it haha! Come on I want sales and that bloody fda

Let’s hope this doesn’t happen

n its trading statement dated 1 August 2013, the Company advised shareholders that it was in discussions with Becton Dickinson ("BD") for an expansion of the supply and distribution agreement of its TB test which, if successful, would lead to additional revenues for the year ended 30 June 2013 of GBP1.0m - GBP1.2m being recognised. The Company today advises that the discussions with BD have not been successfully concluded and the supply and distribution agreement originally entered into in August 2012 has been terminated. The previous guidance for the results for the year ended 30 June 2013 of revenues of GBP5.4m (2012: GBP5.6m) and a loss after tax of GBP1.2m (2012: GBP0.2m) remains unchanged. Development of Genedrive(R) has been the key focus of the Personalised Medicine division, with Preclinical Research Services and Novel Therapies broadly in line with the prior year. Net cash as at 6 September 2013 was GBP6.1m. This will be reduced to GBP5.5m post the repayment of $1m to BD under the terms of the original agreement.

Notwithstanding this development, the Company can report significant progress over the past few months in relation to its assay manufacturing, pre-market support for independent TB clinical studies and preparations for the launch of TB, alongside the development of its expanding menu of infectious disease and pharmacogenomic product applications for Genedrive(R) .

The Company has previously announced the appointment of Xcelris as its distribution channel partner in India. The Company will complete its Indian clinical trials and launch its TB test once the latest test modifications (RIF mutations) have been fully validated, with this work ongoing. The Board believes these modifications represent a significant competitive advantage over existing TB products. We anticipate that this will result in the comparative performance being subject to independent peer review in clinically relevant publications. We will update the market accordingly on publication.

This or next week then

Today from 12:15 pm - 1:15 pm ET, the U.S. Food and Drug Administration (FDA) will host a virtual Town Hall for test developers for SARS-CoV-2. During this Town Hall, the FDA will answer technical questions about the development and validation of tests for SARS-CoV-2.

Trades 126
Vol. Sold 183,225
Sold Value £127.34k
Vol. Bought 423,652
Bought Value £294.44k

Fda ha what the hell hve they been doing for a year

1) The EU deal is taking much longer and is much more difficult than anticipated. It has still not concluded.

Bored of waiting tbh. Fear of losing more money. Trying to build my portfolio etc I’m getting ****ed off with no news etc

Ive sold another 1500 today still hold 95210.. reduced from 100232

That’s them done for the year now..

Does seem odd about bc. The website is constantly updated and growing like you say. About beads I knew they had a couple of 100k made. Meet internal demands so what does that mean?